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Abstract
Background: The prescription of antipsychotics outside overt psychotic conditions
remains controversial, especially in youth where it is relatively widespread. Further-
more, some studies seem to indicate that antipsychotic exposure in individuals at
ultra-high-risk (UHR) for psychosis is associated with higher conversion rates. This
study was set up to test whether the inter-current prescription of antipsychotics in
UHR patients was related to the psychometric threshold for a diagnosis of psychosis.
Methods: The 24-item Brief Psychiatric Rating Scale (BPRS) was used to quantify
treatment response up to 2 years in 125 UHR participants. Standard psychometric
criteria were used to quantify conversion to psychosis. Kaplan-Mayer and Cox pro-
portional hazard survival analysis were applied to determine the impact of having or
not received the prescription of an antipsychotic drug.
Results: Over the study period 30 (24%) subjects received the prescription of an anti-
psychotic. In the sample, there were 31 participants (25%) who had reached the psy-
chometric threshold for conversion to psychosis after 2 years of treatment. UHR
people who received a prescription of antipsychotics during the first 2 years of treat-
ment were statistically more likely to reach the psychometric threshold for conver-
sion to psychosis on the BPRS: Hazard ratio = 3.03 (95%CI: 1.49–6.16); p = .003.
Conclusion: This finding supports the hypothesis that the prescription of antipsy-
chotics within UHR cohorts is to be considered a red flag for higher incipient risk of
conversion to psychosis.
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1 | INTRODUCTION
Whilst there is indubitable, multilevel evidence for the effectiveness
of antipsychotics in the treatment of psychosis (Ceraso et al., 2020;
Zhu et al., 2017), this is still not the case for subthreshold risk
syndromes such as ultra-high-risk (UHR) for psychosis (Yung
et al., 2004; Yung & McGorry, 1996). So far, two small sample size tri-
als have shown that low-dose antipsychotics can reduce prodromal
psychopathology and delay the onset of psychosis in UHR patients
(McGlashan et al., 2006; McGorry et al., 2002). However, the
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protective effects of low-dose antipsychotics in UHR patients are not
long lasting and fade away when controlled at 12-month follow-up
(McGlashan et al., 2006; McGorry et al., 2013). Overall, the prescrip-
tion of antipsychotics in youth remains controversial and critically
depends on cost/benefit ratio. Indeed, antipsychotics are often pre-
scribed in youth for nonpsychotic disorders and for conditions that
did not receive approved indication (Mackie et al., 2020; Olfson
et al., 2015). There is also a concern for the disproportionate prescrip-
tion of antipsychotic medications in youth from underserved commu-
nities (Mackie et al., 2020). Even when the prescription is justified,
youth are thought to be physically and emotionally more vulnerable
to antipsychotics' adverse effects because of their developing physiol-
ogy and more exposed to stigma because of the negative impact on
peer perceptions (Harrison et al., 2012). Evidence on safety outcomes
is limited in children and adolescents and is often indirect or based on
just one study (Krause et al., 2018). Moreover, little information does
exist so far about the long-term effects of antipsychotics on a still-
developing brain (Harrison et al., 2012). Nonetheless, amongst help-
seeking youth accessing early intervention services and deemed to be
UHR for psychosis, the fraction, which has already been exposed to
antipsychotic drug before enrollment is substantial: 20%–30%
depending on the samples (Raballo et al., 2020a; Salazar de Pablo
et al., 2020). According to some surveys, in general, dosages that are
lower than the assumed minimum effective dose are used in these
samples, and it has been suggested that in UHR patients antipsy-
chotics are often used to treat comorbid disorders rather than emerg-
ing psychosis (Fusar-Poli et al., 2020; Kotlicka-Antczak et al., 2020).
Indeed, UHR youth present substantial comorbidity with other mental
disorders (Catalan et al., 2021). It should be noted; however, that cur-
rent guidelines in the field discourage the use of antipsychotics as
first-line treatment in UHR patients, and, in particular, “any long-term
antipsychotic treatment with a primarily preventive purpose is not
recommended” (Schmidt et al., 2015, p. 400).
Recent studies pointed to a negative prognostic impact of anti-
psychotics when prescribed to patients at high risk of psychosis, with
an increased chance of conversion to psychosis after their prescrip-
tion. In a sample of 83 participants diagnosed with a schizotypal disor-
der, Albert et al. (2017) found that treatment with antipsychotics at
baseline was the most significant predictor of conversion to psychosis
at a 3.5-year follow-up. In analysing data from the ShangHai At Risk
for Psychosis (SHARP) study, Zhang, Xu, Tang, et al. (2020) found that
UHR patients who did not receive antipsychotics showed a lower con-
version rate than those who did (17.7% vs. 26.9%; odds ratio = 0.66;
95% confidence interval [CI] = 0.44, 0.98). Moreover, patients who
initiated antipsychotic drugs whilst at clinical high risk of psychosis
had lower remission rates than those who initiated antipsychotic
drugs when already in the first episode of psychosis (Zhang, Xu, Wei,
et al., 2020). In a meta-analysis of 14 studies that reported detailed
information on antipsychotics prescription in UHR patients, Raballo
et al. (2020b) found that UHR patients who had received a prescrip-
tion of antipsychotics before entering the programme of care
(n = 112) had a higher relative risk (RR) of conversion to psychosis
(29% vs. 16%; RR = 1.47; 95%CI: 1.18–1.83) than those who did not
have received any (n = 235). Different interpretations were advanced
to explain these findings. Albert et al. (2017) and Raballo et al. (2020b)
suggested that treatment with antipsychotics is a proxy for elevated
levels of psychiatric symptoms, thus marking a subgroup of individuals
who have per se enhanced risk of conversion to psychosis. Zhang, Xu,
Tang, et al. (2020); Zhang, Xu, Wei, et al. (2020), instead, suggested
that antipsychotics should be considered harmful in subjects at high
risk of psychosis, with no preventive benefits. For these reasons,
Zhang, Xu, Tang, et al. (2020); Zhang, Xu, Wei, et al. (2020) discourage
the prescription of antipsychotics in UHR patients unless presenting
with a quite specific symptoms profile: severe positive and general
symptoms, but mild negative symptoms.
So far, the evidence that the prescription of an antipsychotic drug
is related to the conversion to psychosis in UHR people is limited. On
one side, the start of the first treatment with antipsychotics is typi-
cally considered the endpoint of the DUP (Penttilä et al., 2014), thus it
might be considered a functional equivalent of the conversion to psy-
chosis in UHR patients (Raballo et al., 2020b; Raballo & Poletti, 2019).
On the other side, in current clinical practise, antipsychotics are used
beyond psychosis and, especially in developmental years they are pre-
scribed off-label to treat mood or anxiety symptoms as well as for the
control of disruptive behavioural disorders (Olfson et al., 2015).
1.1 | Aims
This study was set up to test whether the prescription of an antipsy-
chotic drug during the treatment of help-seeking people deemed to
be UHR of psychosis is related to the subsequent risk of trespassing
the psychometric threshold for psychosis. We expected that those
who had received the prescription of antipsychotics during the first
2 years of treatment would be more likely to be found positive for
psychosis according to a predefined psychometric threshold.
2 | METHODS
Data were collected during the routine assessment of the patients
participating in the Programma2000, the early intervention service
operating under the Health Authority of the Niguarda Ca0 Granda
Hospital of Milan (Cocchi et al., 2008). The study complies with the
guidelines of the 1995 Declaration of Helsinki and its revisions (World
Medical Association, 2013). Participants provided informed consent.
The time interval of the study is from 1999 to 2015, when the
Programma2000 was reorganized in both the assessment procedures
and the therapeutic care pathways.
2.1 | Participants
Referrals to Programma2000 arrive from institutionally mediated
pathways (e.g., primary care, district Mental Health, school counsel-
ling, emergency rooms) but can be also self-referrals from
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spontaneously help-seeking individuals (Cocchi et al., 2013). The
served catchment area includes approximately 200 000 inhabitants.
Criteria for referral and preliminary evaluation are: being aged up
to 30 years old and help seeking for impending psychosis. Help-
seeking participants were initially screened with the Italian version of
the Early Recognition Inventory Retrospective Assessment of Symp-
toms checklist (ERIraos-CL). The ERIraos-CL is a 17-item screening
checklist aimed at selecting persons in need of a more in-depth
assessment (Häfner et al., 1992; Raballo et al., 2014). Like the tool
from which it derives, the ERIraos-CL detects at-risk mental states of
psychosis with high sensitivity (Maurer et al., 2018; Rausch
et al., 2013). Patients were deemed to be UHR for psychosis when
they scored ≥12 on the ERIraos-CL (Maurer et al., 2018) and met with
the criteria of the Personal Assessment and Crisis Evaluation (PACE)
Clinic in Melbourne for the identification of young people at incipient
or “UHR” of developing a psychotic disorder (Yung et al., 2004;
Yung & McGorry, 1996). Exclusion criteria were: previous antipsy-
chotic treatment before referral; past or present diagnosis of psycho-
sis in the spectrum of schizophrenia or in the affective spectrum
(bipolar disorder, or unipolar disorder with psychotic features). A
comorbid DSM-IV or DSM-IV-TR diagnosis of substance dependence
was an additional exclusion criterion, whilst substance use/abuse
without dependence was not (Cocchi et al., 2008; Meneghelli
et al., 2010).
2.2 | Measures
The 24-item Brief Psychiatric Rating Scale (BPRS) was used to quan-
tify treatment response up to 2 years. The BRPS is a 24-item measure
of general psychopathology in a Likert format (from one [absent] to
seven [extremely severe]), with higher total scores (ranging from 24 to
168) indicating higher levels of psychopathology (Overall &
Gorham, 1962; Roncone et al., 1999). The BPRS was regularly admin-
istered to the patients at inception and then every 6 months, to assess
levels of psychopathology and its change over time. Raters had a mini-
mum of 2 years of experience in rating patients diagnosed with psy-
chosis and an inter-rater agreement, as measured as intra-class
correlation coefficients, of 0.70 or above when checked on a small
sample of patients (n = 25). To measure conversion to psychosis in
the sample, we applied the criteria for remission in schizophrenia
(Andreasen et al., 2005). According to these criteria, item scores of
mild or less (≤3 using the 1–7 range) on each of the target items
of the BPRS for a 6-month interval define the achievement of remis-
sion in patients with schizophrenia. We assumed, therefore, that
scores higher than three on any of these target items would have
been indicative of conversion to psychosis in UHR young people. The
following seven target items were considered: grandiosity, suspicious-
ness, unusual thought content and hallucinatory behaviour, as indica-
tive of psychoticism/reality distortion; conceptual disorganisation and
mannerisms/posturing, as indicative of disorganisation; blunted affect,
as indicative of negative symptoms and psychomotor poverty.
Participants were tested at a six-month interval (i.e., every
26 weeks approximately) for 2 years. A participant was considered
positive for conversion to psychosis when a score higher than three
was marked on one or more of the seven BPRS target items as
beforehand defined. It should be noted that the threshold for psycho-
sis transition on the BPRS that was selected for this study is quite
conservative and lower than the threshold habitually used on the
Comprehensive Assessment of At-Risk Mental States (CAARMS) or
the Structured Interview for Prodromal Syndromes (SIPS). However,
these tools were not available in Italy when Programma2000 was set
up, and an Italian version was made available only later: 2011 for SIPS
(Comparelli et al., 2011) and 2013 for CAARMS (Raballo et al., 2013).
Nevertheless, the BPRS is an established measure of outcome in clini-
cal trials, and it has been used to measure the effectiveness of psy-
chosocial rehabilitation programmes (Inch et al., 1997) and to assess
changes in psychopathology within UHR patients (Glenthøj
et al., 2016).
Beside the BPRS, the following indicators were used in this study,
as established on a detailed interview with the patient and a key infor-
mant, usually a close relative: gender (boy or girl); age at first contact
(continuous, in years); duration of untreated illness (continuous, in
months, defined as the interval between the onset of the first specific
psychiatric symptom, whether or not related to psychosis, and the
subsequent prescription of the first adequate pharmacological or psy-
chological treatment); past admissions to hospital for psychiatric rea-
sons (yes/no); substance use (yes/no); family history of psychiatric
disorders (yes/no); premorbid functioning (yes/no, according to
whether the patients have had a decline in their functioning at
school/work or with their social relationship with peers in the past
2 years before contact with the centre); drop out of treatment after
the first 2 years for any reason (yes/no).
We also checked the psychometric criterion for conversion to
psychosis against the formal DSM-IV or DSM-IV-TR diagnosis of
schizophrenia-spectrum psychosis made by the therapists at the end
of the 3-year programme. A psychiatrist made the diagnosis after a
thorough revision of the clinical card and discussion with the team of
treatment.
2.3 | Treatment
During the study period treatment at the Programma2000 was based
on a 3-year comprehensive, tailored and flexible intervention package.
The programme included individual psycho-educational and motiva-
tional sessions, cognitive-behavioural psychotherapy, individual family
psycho-education and support, therapeutic group activities
(e.g., anxiety management, assertive and problem-solving training,
etc.), social group activities (e.g., music, multimedia, empowerment,
computer training sessions, etc.), and supportive interventions on
employment, school, compliance with medication, and planning of rec-
reational activities (Cocchi et al., 2008; Meneghelli et al., 2010). Pre-
scription of drugs was on an as-needed basis, that is, when the
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treating staff decided that a patient might benefit from a drug, the
drug was prescribed.
2.4 | Statistics
Preliminary analysis was carried out using the Statistical Package for
Social Sciences (SPSS) version 20. Additional analyses were carried
out in R (R Core Team, 2018) using dedicated packages. All tests were
two-tailed, with alpha set at p < .05.
Two groups were compared: one group including all patients who
received a prescription of antipsychotics at any time during the first
2 years of treatment (APs+), and a control group of patients who did
not receive a prescription of antipsychotics during the treatment
(APs-). Initial comparisons were by chi-square with Yates correction or
Fisher exact test when n < 5 in any cell.
A non-parametric Kaplan–Meier estimation with Cox proportional
hazards model, both univariate and multivariate, including age (contin-
uous) and sex (women as the referent group) as covariates, was used
to calculate differences in survival between the APs + and
TABLE 1 General characteristics of the sample (n = 125). All data are reported as mean (SD); range, or counts (percentage)
Had reached the threshold for psychosis
Gender
Boys 88 (70%) 23 (26%)
Girls 37 (30%) 8 (21%)
Age (years old) 22 (3); range: 16–30
16–20 years old 53 (42%) 15 (28%)
21 years old or older 72 (58%) 16 (22%)
DUI (months) 30 (21); range: 1–60
Less than 12 months 35 (51%) 9 (26%)
12 months or more 70 (35%) 18 (26%)
The DUI could not be determined 18 (14%)
Past admissions for psychiatic reasons
Yes 14 (11%) 5 (36%)
No 111 (89%) 26 (23%)
History of substance use
Yes 22 (18%) 2 (9%)
No 85 (68%) 25 (29%)
Not enough information 18 (14%)
Family history of psychiatric disorders
Yes 67 (54%) 14 (21%)
No 40 (32%) 13 (32%)
Not enough information 18 (14%)
Decline in premorbid functioning
Yes 95 (74%) 20 (30%)
No 23 (18%) 7 (17%)
Not enough information 11 (8%)
Dropout of treatment after 2 years
Yes 38 (30%) 4 (10%)
No 87 (70%) 27 (31%)
BPRS
Baseline 44 (11); range: 19–99
At 6 months 37 (9); range: 24–76 24
At 12 months 33 (8); range: 24–76 4
At 18 months 33 (7); range: 24–62 2
At 24 months 32 (7); range: 24–59 1
Abbreviation: BPRS, Brief Psychiatric Rating Scale.
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APs  groups. Survival was calculated against the negative event of
being positive for psychosis on target items of the BPRS as before-
hand defined. Participants were censored if they did not convert to
psychosis after 104 weeks (= 24 months, hence 2 years) of treatment.
Violations of the proportionality assumption were assessed with the
Schoenfeld Residuals Test. Survival analysis was carried out with
the packages survival (Therneau, 2015) and survminer (Kassambara &
Kosinski, 2018) running in R. The graphical representation of the
results used the package ggplot2 (Wickham, 2016) running in R.
The accuracy of our BPRS threshold for predicting a formal DSM-
IV or DSM-IV-TR diagnosis of schizophrenia-spectrum psychosis was
assessed as the proportion of correct predictions (both true positives
and true negatives) amongst the total number of cases examined and
was expressed as area under the curve (AUC), which is a global
TABLE 2 Differences between participants who received a prescription of antipsychotics during the study period and those who did not. All
data are reported as mean (SD); range, or counts (percentage)
No antipsychotics Antipsychotics
Statistics
n = 95 n = 30
Gender
Boys 69 (73%) 19 (63%) χ2Yates = 0.55; df = 1; p = .46
Girls 26 (27%) 11 (37%)
Age (years old) 22 (3); range: 16–30 21 (3); 17–30 t = 1.11; df = 52.5; p = .27a
16–20 years old 39 (41%) 14 (47%)
21 years old or older 56 (59%) 16 (53%) χ2Yates = 0.11; df = 1; p = .74
DUI (months) 29 (21); range: 1–60 32 (22); 2–60 z = 0.41; p = .680b
Less than 12 months 25 (33%) 10 (33%) χ2Yates = 0.0; df = 1; p = 1.00
12 months or more 50 (67%) 20 (67%)
Missing: n = 20
Past admissions for psychiatic reasons
Yes 7 (7%) 7 (23%) χ2Yates = 4.34; df = 1; p = .04
No 88 (93%) 23 (77%)
History of substance use
Yes 14 (18%) 8 (27%) χ2Yates = 0.50; df = 1; p = .48
No 63 (82%) 22 (73%)
Missing: n = 18
Family history of psychiatric disorders
Yes 49 (64%) 18 (60%) χ2Yates = 0.01; df = 1; p = .90
No 28 (36%) 12 (40%)
Missing: n = 18
Decline in premorbid functioning
Yes 45 (74%) 22 (30%) χ2Yates = 1.46; df = 1; p = .23
No 32 (18%) 8 (17%)
Missing: n = 18
Dropout of treatment
after 2 years
Yes 25 (26%) 13 (43%) χ2Yates = 2.37; df = 1; p = .12
No 70 (74%) 17 (57%)
BPRS
Baseline 43 (12); range: 19–99 47 (10); range: 29–68 z = 2.32; p = .020b
At 6 months 36 (10); range: 24–76 40 (7); range: 29–55 z = 2.95; p = .003b
At 12 months 32 (8); range: 24–76 34 (6); range: 24–54 z = 1.24; p = .214b
At 18 months 31 (7); range: 24–62 33 (7); range: 24–56 z = 2.12; p = .034b
At 24 months 31 (6); range: 24–59 31 (5); range: 24–41 z = 0.92; p = .356b
aWelch's t-test (because of unequal variance).
bNon-parametric Mann–Whitney U test.
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measure of test performance, with 95% CI. Values of AUC between
0.80 and 0.90 are considered excellent, between 0.70 and 0.80 are
considered acceptable (Altman et al., 2000).
3 | RESULTS
The sample included 125 young people (aged between 16 and 30)
who were identified as UHR for psychosis according to the predefined
criteria. Table 1 summarizes the general characteristics of the sample.
Overall, over the 2 years follow up, 30 (24%) subjects received
the prescription of an antipsychotic (three subjects started with a typi-
cal antipsychotic then were switched to an atypical, second-
generation antipsychotic, like the others). Those who had received a
prescription of antipsychotics during the study period did not differ in
age, gender proportion or DUI from those who had not received one,
but were more likely to have had a past admission to the hospital for
psychiatric reasons (Table 2).
The main difference between the two groups concerned the scores
on the BPRS. Those who had received antipsychotics had higher scores
on the BPRS at baseline, at 6 months, and at 18 months, suggesting
that they were modestly more severe at inception and showed greater
levels of psychopathology also during the study period.
At the end of the first 2-year period of treatment, in the sample
there were 31 participants (25%) who had reached the psychometric
threshold for conversion to psychosis. Those who had received a pre-
scription of antipsychotics during the study period were more likely to
have reached the threshold for conversion to psychosis (14 out of
30 [47%]) than those who did not receive a prescription of antipsy-
chotics (17 out of 95 [18%]): χ2Yates = 8.63; df = 1; p = .003.
In the sample eight UHR patients received a formal diagnosis of
schizophrenia-spectrum psychosis at the end of the three-year pro-
gramme, five (out of 31; 16%) amongst those who reached the
psychometric threshold for conversion to psychosis at the end of the
first 2 years of treatment and three (out of 94; 3%) amongst those
who did not (Fisher exact test: p = .022). Predictive accuracy of the
BPRS threshold was 0.76 (95% CI: 0.68–0.84).
3.1 | Survival analysis
UHR people who received a prescription of antipsychotics during the
first 2 years of treatment were statistically more likely to reach
the psychometric threshold for conversion to psychosis on the BPRS at
follow-up: Hazard ratio (HR) = 3.03 (95%CI: 1.49–6.16); Likelihood ratio
test: 8.69; d.f. = 1; p = .003; log-rank test: 10.43; p = .001 (Figure 1).
No evidence against the proportionality assumption could be
found (Schoenfeld Residuals Test: χ2 = 0.25, p = .61). The Cox regres-
sion analysis confirmed a greater chance of reaching the psychometric
threshold for conversion to psychosis on the BPRS amongst those
who received a prescription of antipsychotics than amongst
those who did not receive it, even when sex and age were accounted
for (Table 3).
When taking into account factors that might impact on the pri-
mary outcome, participants who drop out of treatment after the first
2 years (HR = 0.32; 0.10–0.99, p = .049) and those with a history of
substance use (HR = 0.23; 0.04–1.11, p = .068) were marginally less
likely to reach the psychometric threshold for conversion to psychosis
on the BPRS. Again, no violation against the proportionality assump-
tion could be found (see Table 3).
4 | DISCUSSION
This study showed that a prescription of antipsychotics in UHR is sta-
tistically linked to a greater chance of reaching a psychometric
F IGURE 1 Survival curves with the number at risk by time, based on (a) Kaplan–Meier estimates of the negative event as representative of
positivity for psychosis on the BPRS according to the prescription of antipsychotics (+ or –) and (b) cumulative hazard of the positivity for
psychosis on the BPRS of the same data. BPRS, Brief Psychiatric Rating Scale
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threshold for conversion to psychosis at follow-up. The most obvious
explanation is that UHR people who show impending signs of more
severe psychopathology are more likely to receive a prescription of
antipsychotics by the treating clinicians who aim at decreasing symp-
toms' impact and avert the risk of conversion to psychosis. In the sam-
ple, those who had received antipsychotics had modestly higher
scores on the BPRS at baseline and 6 months and again at 18 months.
This might suggest that they were more likely to show symptoms
indicative of possible conversion to psychosis or anyhow a slightly
more severe overall psychopathological outlook although still below
the formal psychometric threshold for conversion to psychosis.
Indeed, the naturalistic threshold adopted in this study is the one at
which the prescription of antipsychotics is expected to be started in
clinical practise (presence of persisting and non-negligible symptoms
of psychosis). The finding suggests that the prescription of an antipsy-
chotic is indeed a marker of possible conversion to psychosis in UHR
patients, and that within UHR populations the intercurrent prescrip-
tion of antipsychotics could be considered a functional equivalent of
such conversion (Raballo et al., 2020b; Raballo & Poletti, 2019).
This result is corroborated by the observation that those who
dropped out of treatment before the termination of the three-year
programme were less likely to reach the psychometric threshold for
conversion to psychosis. This may depend on people dropping out
of treatment when they are not so severe to instigate scrutiny and
assertive outreach after their anticipated conclusion of the pro-
gramme. Essentially, people with more severe symptoms are less
likely to leave the treatment since they receive more intensive care
according to the tailored protocol. Also those with a history of sub-
stance use were marginally less likely to reach the psychometric
threshold for conversion to psychosis. These patients may have
benefitted from a combination of the tailored protocol of care for
the UHR symptoms with a dedicated treatment for substance
use/abuse. The closer scrutiny resulting from the greater attention
to the risk of psychosis in those with substance use (Rapado-Castro
et al., 2015) may have prevented the emergence of severe symp-
toms of psychosis in this specific subgroup. For example, UHR
patients often have a history of cannabis use (Farris et al., 2020),
and those with a history of cannabis use have more severe symp-
toms of psychosis (Carney et al., 2017). However, despite being fre-
quently related to conversion to psychosis, cannabis use was not
statistically associated with conversion to psychosis in a recent
meta-analysis: RR = 1.11, 95% CI = 0.89–1.37 (Farris et al., 2020).
The reason may be that substance use, being a well-known marker
of risk for psychosis (Rapado-Castro et al., 2015), prompts the appli-
cation of more intensive care that may eventually protect against
the risk of conversion to psychosis.
In this study, we have used a threshold for conversion to psycho-
sis based on the BPRS that is lower than the threshold habitually used
on the CAARMS or the SIPS. Nevertheless, the predictive accuracy of
our procedure, when tested against a formal clinical diagnosis of -
schizophrenia-spectrum psychosis, resulted comparable to the esti-
mated accuracy of the CAARMS (AUC = 0.79 95% CI: 0.75–0.83;
Oliver et al., 2018) and marginally lower than the one of the SIPS
(AUC = 0.80; 95% CI: 0.66–0.95; Zhang et al., 2019).
TABLE 3 Univariate and multivariate cox proportional regression analyses of the primary endpoint (psychometric conversion to psychosis) in
the sample (n = 125)
HR 95%ci p-value Likelihood ratio Schoenfeld residuals test
Univariate
AP+ 3.03 1.49–6.16 .002 LR = 8.69; p = 0.003 χ2 = 0.25, p = .61
Multivariate
First analysis
AP+ 3.11 1.52–6.37 .002 LR = 9.46; p = 0.02 χ2 = 0.98, p = .322
Sex 1.30 0.61–3.11 .437 χ2 = 0.86, p = .353
Age 0.98 0.88–1.09 .771 χ2 = 2.32, p = .127
Multivariate
Second analysis
AP+ 3.92 1.73–8.91 .001 LR = 24.59; p = 0.003 χ2 = 0.31, p = .578
Sex (boys) 1.24 0.50–3.07 .640 χ2 = 0.34, p = .561
Age (continuous) 0.98 0.87–1.09 .692 χ2 = 1.54, p = .214
DUI (continuous) 0.99 0.97–1.01 .576 χ2 = 0.01, p = .925
Past admissions for psychiatic reasons (yes) 2.45 0.67–8.92 .173 χ2 = 0.06, p = .799
History of substance use (yes) 0.23 0.04–1.11 .068 χ2 = 0.09, p = .757
Family history of psychiatric disorders (yes) 0.52 0.22–1.23 .136 χ2 = 1.40, p = .236
Dropout of treatment after 2 years (yes) 0.32 0.10–0.99 .049 χ2 = 1.34, p = .247
Decline in premorbid functioning (yes) 1.60 0.58–4.42 .360 χ2 = 0.01, p = .971
Note: AP+ = Had received the prescription of an antipsychotic during the first 2 year of treatment.
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4.1 | Strengths and limitations
The main strength of the study is the availability of longitudinal data
that was prospectively collected for purposes unrelated to the aims of
the study thus limiting the risk of bias in the subsequent analysis.
Although BPRS is a suboptimal tool for the clinical profiling of UHR
help-seekers, the psychometric threshold that we used to define the
conversion to psychosis showed an acceptable relationship with
the formal diagnosis for schizophrenia-spectrum psychosis as formu-
lated by the treating staff at the end of the three-year programme of
care, thus corroborating its validity. However, we were unable to have
temporal data about the prescription of the antipsychotics. We only
had the information about whether or not a patient received the pre-
scription of an antipsychotic during the first 2 years of treatment, thus
we were unable to precisely relate the prescription of the antipsy-
chotic to the later trespassing of the psychometric threshold for con-
version to psychosis.
5 | CONCLUSIONS
The intercurrent prescription of antipsychotics in UHR individuals
attending Programma 2000 was statistically linked to a higher risk of
trespassing the psychometric threshold for conversion to psychosis.
When psychopathology becomes more severe and subthreshold
symptoms of psychosis more conspicuous, treating clinicians tend to
prescribe antipsychotics to mitigate psychopathological worsening.
Thus, antipsychotic prescription in UHR patients would be a proxy for
a higher severity subgroup with stronger potential to develop psycho-
sis. However, we cannot exclude that for some patients, the prescrip-
tion of an antipsychotic drug might prompt a sensibilization of the
dopamine receptors, which may favour a further rebound of symp-
toms until conversion to psychosis (Chouinard et al., 2017). In-depth
scrutiny of the symptoms' profile is thus necessary to wisely ponder
the best, individualized treatment option for UHR patients (Zhang, Xu,
Tang, et al., 2020; Zhang, Xu, Wei, et al., 2020), balancing psycho-
pharmacotherapy with psychotherapy approaches, such as cognitive-
behavioural therapy, which offers first-line protection from conver-
sion to psychosis (Devoe et al., 2020).
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